Musk’s Neuralink Aims to Enroll Three Patients for Brain Implant Study

Neuralink, the brain-chip company founded by Elon Musk, intends to recruit three participants for an evaluation of its device as per information available on the U.S. government’s clinical trials database. This study is anticipated to span several years for completion.

Initially, Neuralink planned to include ten patients in this trial, as reported by [Reuters](https://www.reuters.com/investigates/special-report/neuralink-musk-fda/) last year. The brain implant is designed to help people with spinal cord injuries manipulate computers and other devices just by thinking, which could drastically improve their quality of life.

The research is scheduled to complete its first phase in 2026 and conclude entirely in 2031. It is open to individuals aged 22 to 75 suffering from quadriplegia due to spinal injuries or amyotrophic lateral sclerosis (ALS). Candidates must exhibit significant mobility limitations persisting for over a year and have a life expectancy of at least 12 months.